These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 24717262

  • 1. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
    Blanchet M, Sureau C, Labonté P.
    Antiviral Res; 2014 Jun; 106():111-5. PubMed ID: 24717262
    [Abstract] [Full Text] [Related]

  • 2. Irbesartan, an FDA approved drug for hypertension and diabetic nephropathy, is a potent inhibitor for hepatitis B virus entry by disturbing Na(+)-dependent taurocholate cotransporting polypeptide activity.
    Wang XJ, Hu W, Zhang TY, Mao YY, Liu NN, Wang SQ.
    Antiviral Res; 2015 Aug; 120():140-6. PubMed ID: 26086883
    [Abstract] [Full Text] [Related]

  • 3. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S.
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [Abstract] [Full Text] [Related]

  • 4. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus.
    Yan H, Li W.
    Dig Dis; 2015 Apr; 33(3):388-96. PubMed ID: 26045274
    [Abstract] [Full Text] [Related]

  • 5. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.
    He W, Ren B, Mao F, Jing Z, Li Y, Liu Y, Peng B, Yan H, Qi Y, Sun Y, Guo JT, Sui J, Wang F, Li W.
    PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143
    [Abstract] [Full Text] [Related]

  • 6. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
    Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W.
    J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
    [Abstract] [Full Text] [Related]

  • 7. Inhibitors of hepatitis B virus attachment and entry.
    Lempp FA, Urban S.
    Intervirology; 2014 Mar; 57(3-4):151-7. PubMed ID: 25034482
    [Abstract] [Full Text] [Related]

  • 8. Strategies to inhibit entry of HBV and HDV into hepatocytes.
    Urban S, Bartenschlager R, Kubitz R, Zoulim F.
    Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
    [Abstract] [Full Text] [Related]

  • 9. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
    Kaneko M, Watashi K, Kamisuki S, Matsunaga H, Iwamoto M, Kawai F, Ohashi H, Tsukuda S, Shimura S, Suzuki R, Aizaki H, Sugiyama M, Park SY, Ito T, Ohtani N, Sugawara F, Tanaka Y, Mizokami M, Sureau C, Wakita T.
    J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
    [Abstract] [Full Text] [Related]

  • 10. Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes.
    Lempp FA, Wiedtke E, Qu B, Roques P, Chemin I, Vondran FWR, Le Grand R, Grimm D, Urban S.
    Hepatology; 2017 Sep; 66(3):703-716. PubMed ID: 28195359
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
    Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low BE, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, Giersch K, Gerges S, Seneca K, Pais MA, Frankel AS, Chiriboga L, Cullen J, Nahass RG, Lutgehetmann M, Toettcher JE, Wiles MV, Schwartz RE, Ploss A.
    Sci Transl Med; 2018 Jun 27; 10(447):. PubMed ID: 29950446
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening.
    Kirstgen M, Müller SF, Lowjaga KAAT, Goldmann N, Lehmann F, Alakurtti S, Yli-Kauhaluoma J, Baringhaus KH, Krieg R, Glebe D, Geyer J.
    Viruses; 2021 Jul 29; 13(8):. PubMed ID: 34452354
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Selective hepatitis B and D virus entry inhibitors from the group of pentacyclic lupane-type betulin-derived triterpenoids.
    Kirstgen M, Lowjaga KAAT, Müller SF, Goldmann N, Lehmann F, Alakurtti S, Yli-Kauhaluoma J, Glebe D, Geyer J.
    Sci Rep; 2020 Dec 10; 10(1):21772. PubMed ID: 33303817
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. NTCP opens the door for hepatitis B virus infection.
    Yan H, Liu Y, Sui J, Li W.
    Antiviral Res; 2015 Sep 10; 121():24-30. PubMed ID: 26071008
    [Abstract] [Full Text] [Related]

  • 19. Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.
    Yu Y, Li S, Liang W.
    Emerg Microbes Infect; 2018 Jul 26; 7(1):134. PubMed ID: 30050063
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.